Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial.

ABSTRACT:

Background and objectives

Hyperphosphatemia is common among recipients of maintenance dialysis and is associated with a higher risk of mortality and cardiovascular events. A large randomized trial is needed to determine whether lowering phosphate concentrations with binders improves patient-important outcomes. To inform such an effort we conducted a pilot randomized controlled trial.

Design, setting, participants, & measurements

We conducted a randomized controlled trial of prevalent hemodialysis recipients already receiving calcium carbonate as a phosphate binder at five Canadian centers between March 31, 2014 and October 2, 2014. Participants were randomly allocated to 26 weeks of an intensive phosphate goal of 2.33-4.66 mg/dl (0.75-1.50 mmol/L) or a liberalized target of

SUBMITTER: Wald R 

PROVIDER: S-EPMC5460712 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature